^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ALA-101

i
Other names: ALA-101, CD19-directed CAR-iNKT, CAR19-iNKT
Associations
Trials
Company:
Arovella Therap, Imperial College London
Drug class:
CD19 inhibitor, iNKT agonist
Related drugs:
Associations
Trials
over1year
Engineering allogeneic off-the-shelf CD19-directed CAR-iNKT cells without additional genetic manipulations for the treatment of hematological malignancies (AACR 2023)
These data demonstrate a unique, off the shelf CAR19-iNKT cell platform for targeting hematological malignancies that combines the specificity of CD19 targeting CAR with the innate features of iNKT cells. The data indicates that iNKT cells are a potent cell type for generating allogeneic off the shelf products for treating a broad spectrum of hematological malignancies and solid tumors by targeting different receptors on the respective tumors.
IO biomarker
|
CD19 (CD19 Molecule)
|
CD19 expression
|
ALA-101